TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
3D Medicines, Inc. ( (HK:1244) ) has issued an announcement.
3D Medicines Inc. announced its audited financial results for the year ended December 31, 2024, highlighting a 29.8% decrease in revenue to RMB445.6 million due to intense market competition. Despite this, the company saw a 15.9% increase in sales in the second half of the year compared to the first half, indicating a positive sales trend. The company’s gross profit decreased by 30.2% to RMB409.1 million, with a slight decline in gross profit margin due to increased sales-related taxes and product quality costs. Research and development expenses significantly decreased by 57.5%, attributed to reductions in third-party contracting expenses, employee benefits, and costs associated with in-licensed drug candidates.
More about 3D Medicines, Inc.
3D Medicines Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. Its primary product is Envafolimab, a subcutaneously-injectable PD-L1, which it sells to pharmacy operating companies and distributors.
YTD Price Performance: 28.25%
Average Trading Volume: 288,092
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.02B
See more insights into 1244 stock on TipRanks’ Stock Analysis page.